Consortium for Safety Assessment using Human iPS Cells (CSAHi), Japan.
Curr Pharm Biotechnol. 2020;21(9):773-779. doi: 10.2174/1389201021666200131123524.
Human hepatocytes are essential cell types for pharmacokinetics and the safety evaluation of pharmaceuticals. However, widely used primary hepatocytes with individual variations in liver function lose those functions rapidly in culture. Hepatic cell lines are convenient to use but have low liver functions. Human-Induced Pluripotent Stem (hiPS) cells can be expanded and potentially differentiated into any cell or tissue, including the liver. HiPS cell-derived Hepatocyte-Like Cells (hiPSHeps) are expected to be extensively used as consistent functional human hepatocytes. Many laboratories are investigating methods of using hiPS cells to differentiate hepatocytes, but the derived cells still have immature liver functions. In this paper, we describe the current uses and limitations of conventional hepatic cells, evaluating the suitability of hiPS-Heps to pharmacokinetics and the safety evaluation of pharmaceuticals, and discuss the potential future use of non-conventional non-monolayer culture methods to derive fully functional hiPS-Heps.
人肝细胞是药代动力学和药物安全性评估的重要细胞类型。然而,具有个体肝功能差异的常用原代肝细胞在培养中迅速失去这些功能。肝细胞系使用方便,但肝功能较低。人诱导多能干细胞(hiPS)可以扩增,并有可能分化为任何细胞或组织,包括肝脏。hiPS 细胞衍生的肝细胞样细胞(hiPSHeps)有望广泛用作具有一致功能的人肝细胞。许多实验室都在研究使用 hiPS 细胞分化肝细胞的方法,但这些细胞仍然具有不成熟的肝功能。在本文中,我们描述了传统肝细胞的当前用途和局限性,评估了 hiPS-Heps 在药代动力学和药物安全性评估中的适用性,并讨论了使用非传统非单层培养方法来衍生完全功能的 hiPS-Heps 的潜在未来用途。